{"id":265153,"date":"2026-09-23T15:32:19","date_gmt":"2026-09-23T10:02:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=265153"},"modified":"2026-09-23T15:32:19","modified_gmt":"2026-09-23T10:02:19","slug":"natco-pharma-vs-ajanta-pharma-vs-ipca-laboratories","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/natco-pharma-vs-ajanta-pharma-vs-ipca-laboratories\/","title":{"rendered":"Natco Pharma vs Ajanta Pharma vs Ipca Laboratories: Which Stock Should You Track"},"content":{"rendered":"

Natco Pharma PE 12.75, mkt cap Rs 14,597 crore. Ajanta Pharma PE 38.75, mkt cap Rs 43,981 crore. Ipca Laboratories PE 36.76, mkt cap Rs 50,543 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Natco Pharma vs Ajanta Pharma vs Ipca Laboratories is a side-by-side comparison of three companies from the API and Specialty Pharma space. On this comparison, Natco Pharma carries a market capitalisation of about Rs 14,597 crore against Rs 43,981 crore for Ajanta Pharma and Rs 50,543 crore for Ipca Laboratories, with return on equity of 15.38%, 23.33% and 14.15% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/div>\n

Natco Pharma vs Ajanta Pharma vs Ipca Laboratories starts with the core numbers most investors compare within the API and Specialty Pharma segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n

All three names sit in the API and Specialty Pharma bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n